BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1015 related articles for article (PubMed ID: 22699206)

  • 21. Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival.
    Kim HR; Seo M; Nah YW; Park HW; Park SH
    Nucl Med Commun; 2018 Jul; 39(7):691-698. PubMed ID: 29893751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
    Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
    Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of FDG PET/CT-Derived Parameters in Pancreatic Adenocarcinoma at Initial PET/CT Staging.
    Chirindel A; Alluri KC; Chaudhry MA; Wahl RL; Pawlik TM; Herman JM; Subramaniam RM
    AJR Am J Roentgenol; 2015 May; 204(5):1093-9. PubMed ID: 25905947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
    Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
    J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.
    Piperkova E; Raphael B; Altinyay ME; Castellon I; Libes R; Sandella N; Heiba S; Abdel-Dayem H
    Clin Nucl Med; 2007 Jun; 32(6):429-34. PubMed ID: 17515747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
    Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
    Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of F-18-FDG PET/CT findings between pancreatic solid pseudopapillary tumor and pancreatic ductal adenocarcinoma.
    Kim YI; Kim SK; Paeng JC; Lee HY
    Eur J Radiol; 2014 Jan; 83(1):231-5. PubMed ID: 24290142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment.
    Nasu K; Abe W; Takai N; Tomonari K; Narahara H
    Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.
    Burge ME; O'Rourke N; Cavallucci D; Bryant R; Francesconi A; Houston K; Wyld D; Eastgate M; Finch R; Hopkins G; Thomas P; Macfarlane D
    HPB (Oxford); 2015 Jul; 17(7):624-31. PubMed ID: 25929273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
    Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
    J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma.
    Kato H; Kuwano H; Nakajima M; Miyazaki T; Yoshikawa M; Ojima H; Tsukada K; Oriuchi N; Inoue T; Endo K
    Cancer; 2002 Feb; 94(4):921-8. PubMed ID: 11920459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of 18F-FDG PET/CT in the diagnosis and staging of extramammary Paget's disease.
    Tian Y; Wu HB; Li DL; Li HS; Zhou WL; Wang QS
    Nucl Med Commun; 2015 Sep; 36(9):892-7. PubMed ID: 25932540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.
    Yeh R; Dercle L; Garg I; Wang ZJ; Hough DM; Goenka AH
    Abdom Radiol (NY); 2018 Feb; 43(2):415-434. PubMed ID: 29143875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG PET-CT in cervical cancer: relationship between primary tumor FDG uptake and metastatic potential.
    Yilmaz M; Adli M; Celen Z; Zincirkeser S; Dirier A
    Nucl Med Commun; 2010 Jun; 31(6):526-31. PubMed ID: 20215979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.